Foreign Media: Chinese innovative medical device companies are accelerating their expansion into the European market, driven by increasing domestic policy pressures and profit challenges.
From January to May 2026, procurement of medical devices declined by approximately 12%, partly due to hospital anti-corruption investigations, which have put pressure on revenue for major medical device manufacturers in the first half of the year. Since public hospitals account for about 84% of patient visits in China and are also the primary buyers of medical equipment, policy changes have a significant impact on businesses.
Under this backdrop, an increasing number of Chinese medical device companies are seeking overseas growth. Jianshi Technology, a heart medical device company based in Ningbo, has become the latest example—its innovative product, LuX-Valve Plus, has obtained CE certification under the EU’s new Medical Device Regulation (MDR), enabling it to enter the European market. This product replaces a damaged tricuspid valve via a minimally invasive venous approach, avoiding open-chest surgery. The company stated that this certification marks a crucial milestone in its internationalization strategy. Meanwhile, the rise of global trade protectionism has added further challenges for Chinese enterprises venturing abroad.
Original Source: toutiao.com/article/1870671685732352/
Disclaimer: The views expressed in this article are solely those of the author.